Does quercetin reduce inflammation, calm allergies or slow aging?

Quercetin belongs to a class of plant compounds called flavonols. It works through several distinct pathways in the body, which helps explain why it shows up in research for so many different conditions.

Anti-Inflammatory Action

Quercetin inhibits key inflammatory enzymes — including COX-2 and LOX — and downregulates the production of pro-inflammatory cytokines like TNF-α, IL-1β, and IL-6^1,2. This is similar in some ways to how NSAIDs like ibuprofen work, but without the same GI side effects. In a double-blind trial in women with rheumatoid arthritis, 500 mg/day for 8 weeks significantly reduced morning stiffness, pain scores, and TNF-α levels compared to placebo¹.

Natural Antihistamine

One of quercetin's most practical applications is seasonal allergy relief. It stabilizes mast cells — the immune cells that release histamine during allergic reactions — reducing the release of histamine and other inflammatory mediators. Research comparing quercetin directly to cromolyn, a pharmaceutical mast cell stabilizer, found quercetin outperformed it in blocking IL-8 and TNF release from human mast cells³. This makes it a useful natural option for hay fever, food sensitivities, and skin reactions.

Senolytic Effects

"Senolytics" are compounds that selectively eliminate senescent cells — aging, dysfunctional cells that accumulate with age and drive chronic inflammation through what's called the senescence-associated secretory phenotype (SASP). Quercetin, often combined with the cancer drug dasatinib, is one of the first compounds tested in humans for this purpose. A Mayo Clinic trial found the combination actually reduced markers of senescent cell burden in fat tissue biopsies⁴. This is early-stage research, but it's one of the more exciting areas in longevity science.

Cardiovascular Support

A meta-analysis of 7 randomized controlled trials found quercetin supplementation reduced systolic blood pressure by an average of 3 mmHg, with stronger effects at doses above 500 mg/day⁵. It also improves endothelial function and has mild LDL-oxidation–inhibiting effects.

Practical Dosage

• Food sources: Capers (highest concentration), red onions, apples with skin, broccoli, kale, berries
• Supplement range: Most research uses 500–1,000 mg/day
• Bioavailability matters: Quercetin from food (glycoside forms from onions) absorbs faster and more completely than quercetin powder (aglycone form)⁷. Supplement forms with added bromelain or vitamin C, or "phytosome" formulations, improve absorption
• Safe for most people at typical supplement doses; may interact with blood thinners and some medications — check with a doctor if relevant

Anti-Inflammatory: Clinical Trials and Meta-Analysis

The 2017 RCT by Javadi et al. (PMID 27710596) enrolled 50 women with stable rheumatoid arthritis and randomized them to 500 mg quercetin or placebo daily for 8 weeks. The quercetin group showed significant reductions in early morning stiffness (p < 0.001), morning pain (p = 0.001), and post-activity pain (p = 0.001), along with decreased serum TNF-α. C-reactive protein trended lower but did not reach significance, possibly due to study size. This was a well-designed double-blind trial with objective biomarkers alongside subjective symptom reports.

The 2020 meta-analysis by Ou et al. (PMID 31213101) pooled data from multiple RCTs and found significant reductions in CRP among participants receiving quercetin, particularly at doses above 500 mg/day and in populations with elevated baseline inflammation. Effect sizes were modest in absolute terms, which is typical for dietary interventions, but the directionality was consistent across trials.

Mast Cell Stabilization: Comparison with Pharmaceutical Cromolyn

Weng et al. (PMID 22470478) conducted both in vitro and human studies comparing quercetin to cromolyn sodium, a pharmaceutical mast cell stabilizer used for allergic conditions. In human mast cell cultures, quercetin inhibited IL-8 and TNF release more effectively than cromolyn at equivalent concentrations. In a small human study, topical quercetin reduced contact dermatitis and photosensitivity reactions. The mechanism involves blockade of calcium influx into mast cells and suppression of NF-κB signaling. This study is notable for using head-to-head comparison with an established pharmaceutical rather than placebo alone.

Senolytic Research: First Human Trial

The landmark Mayo Clinic trial by Hickson et al. (PMID 31542391) was the first clinical study to show that senolytics actually reduce senescent cell burden in living humans. Eleven patients with diabetic kidney disease received three intermittent 3-day courses of dasatinib (100 mg/day) plus quercetin (1,000 mg/day). Adipose tissue biopsies before and after showed significant reductions in p16^INK4a and p21^CIP1 expression (markers of cellular senescence), reduced SA-β-galactosidase activity, and decreased SASP factors. Physical function also improved on several measures. This was an uncontrolled pilot study (n=11, no placebo arm), so results must be interpreted cautiously — but the effect on tissue biomarkers was biologically meaningful. Ongoing larger trials are building on this foundation.

Cardiovascular: Blood Pressure Meta-Analysis

Serban et al. (PMID 27405810), published in the Journal of the American Heart Association, pooled 7 RCTs involving 587 patients. Quercetin supplementation produced a weighted mean reduction of −3.04 mmHg in systolic blood pressure (95% CI: −5.26 to −0.82 mmHg, p = 0.007). The effect was more pronounced in trials using doses above 500 mg/day and in participants with higher baseline blood pressure. Diastolic blood pressure changes were non-significant. A 3 mmHg reduction in population-level SBP corresponds to meaningfully reduced cardiovascular event rates, though individual effects will vary.

Antiviral Evidence

Di Pierro et al. conducted a 2-week, randomized, open-label pilot trial of 42 COVID-19 outpatients: 21 received standard care plus a bioavailable quercetin phytosome and 21 received standard care alone⁶. After one week, 16 patients in the quercetin group had tested negative for SARS-CoV-2 versus 2 in the standard-care group, and the time to a negative test was significantly shorter with quercetin. Symptoms were milder, and levels of LDH, ferritin, CRP, and D-dimer fell more with quercetin. One patient in the standard-care group died by day 20. Limitations include the small sample size, the open-label design, and the specific phytosome formulation used. This is preliminary evidence and should not be interpreted as a treatment recommendation.

Bioavailability: Why Form Matters

Graefe et al. (PMID 11361045) conducted a pharmacokinetic study in humans comparing quercetin aglycone (pure quercetin powder) to quercetin-4'-glucoside from onions and quercetin-3-rutinoside from buckwheat. The onion-derived glucoside was absorbed significantly faster (Tmax ~0.9 hours vs. 7+ hours) and to a greater absolute extent than the aglycone. Rutinoside had the poorest absorption. This has practical implications: quercetin supplements using standard quercetin powder may have lower bioavailability than food sources or specialized formulations. "Quercetin phytosome" (bound to phosphatidylcholine) and quercetin combined with bromelain are common approaches to improving absorption in supplements.

Overall Evidence Assessment

Quercetin has a solid evidence base for anti-inflammatory and mast cell–stabilizing effects, with human RCT data supporting modest but real-world-relevant benefits. The senolytic research is early-stage but scientifically compelling — it's among the only compounds with human biopsy evidence of reducing senescent cell burden. Cardiovascular benefits appear real but modest. Bioavailability varies significantly by formulation. Safety profile is excellent at doses up to 1,000 mg/day in short- to medium-term studies.